Following, somewhat belatedly, in the footsteps of Novartis and Celgene, Pfizer has entered the chimeric antigen receptor T-cell (CAR-T) immunotherapy field by forming a broad multitarget alliance with French biotech Cellectis that has a potential value in excess of US$2.8 B. The deal provides Pfizer with exclusive rights to pursue the development and commercialisation of CAR-T therapies directed against 15 cancer targets that it has selected. Unlike the autologous CAR-T therapies currently in clinical development, Cellectis’ CAR-T platform offers an allogeneic approach by utilising engineered T-cells from a single donor for use in multiple patients.